Back to search

Article

Gastric cancer combination therapy by siRNA-mediated NRF2 silencing and paclitaxel

2023-06-28

Abstract excerpt

<h4>Background: </h4> Gastric cancer (GC) is a highly chemoresistant malignancy with a poor prognosis. Paclitaxel's low response rate as second-line chemotherapy for advanced GC has prompted intensive research into its molecular basis and prospective targeted therapies to enhance its therapeutic efficacy. The objective of this study was to investigate the synergistic effects of NRF2 silencing in combination with p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6de0ff67-c19d-5322-b95b-181e7b18cb74
DOI
10.21203/rs.3.rs-3095925/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Gastric cancer combination therapy by siRNA-mediated NRF2 silencing and paclitaxelDOI 10.21203/rs.3.rs-3095925/v1
Select a neighboring publication to make it the new centre.